Myasthenia gravis and acetylcholine receptor antibodies: A clinico immunological correlative study on South Indian patients

P. S. Bindu, M. Nirmala, S. A. Patil, A. B. Taly

Departments of Neurology and Neuromicrobiology, National Institute of Mental Health and Neurosciences, Bangalore, India

Abstract

Acquired myasthenia Gravis (MG), a disorder of impaired neuromuscular transmission is recognized as an autoimmune disorder, with a majority of the patients having antibodies against acetylcholine receptor (AChR antibodies) in the serum. Aim and Objectives: To correlate the AChR antibody status with the clinical characteristics of patients with myasthenia gravis. Study Design: Retrospective and prospective study. Materials and Methods: This study was carried out in patients with definite MG, attending the Neurology services of the National Institute of Mental Health and Neurosciences, Bangalore, India, during the period 1999-2003. The AChR antibody status was determined using the direct and indirect enzyme linked immunosorbent assay (ELISA) technique. Results: There were 165 patients in this study (M : F :: 1.5 : 1). The overall seropositivity rate was 59.4%. Seropositive patients had higher age of onset and presentation, and more frequent occurrence of crises, both at presentation and at any time during the course. Other parameters, viz. gender of the patient, Osserman staging, thymic enlargement on CT and remission during follow-up did not differ between the two groups. Conclusion: This communication reports the result of AChR antibody assay in a large cohort of patients, using a simple diagnostic tool, namely direct and indirect ELISA technique. In addition, the characteristics of a large cohort of patients with seronegative myasthenia gravis are described.

Keywords

AChR antibodies, enzyme linked immunosorbent assay, myasthenia gravis, seronegative myasthenia Gravis

For correspondence:

A. B. Taly, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India. E-mail: abtaly@yahoo.com

Ann Indian Acad Neurol 2008;11:242-4
using both direct and indirect ELISA techniques\cite{3,4} and the test was considered positive only when both the tests were positive.

**Results**

In this study, the AChR antibody status of a large cohort of patients with myasthenia gravis was evaluated. Diagnosis of MG was established by typical clinical history (100%), fatigability tests (97.5%), positive neostigmine test (97.2%) and decrement of more than 10% on repetitive nerve stimulation test (87.8%). There were 165 patients with definite acquired myasthenia gravis as defined above. This included 98 males and 67 females patients (M : F :: 1.5 : 1). Their serological status in the different groups is shown in Table 1. Seropositive and seronegative groups were compared with regard to age at onset and presentation, gender, presence or absence of crisis at the time of presentation or at any time during the course of follow-up, presence of abnormal thymus on CT scan of the chest among individuals above the age of 15 years, history of remissions, and mortality [Table 2]. It was noted that seropositive patients had higher age of onset and presentation, and more frequent occurrence of crises, both at presentation and at any time during the course. Other parameters, viz.gender of the patient, Osserman staging, thymic enlargement on CT and remission during follow-up did not differ between the two groups.

**Table 1: Serological status of patients with myasthenia gravis**

| Group               | n  | Seropositive | Percentage |
|---------------------|----|--------------|------------|
| Myasthenia gravis   | 165| 98           | 59.4       |
| Ocular              | 39 | 20           | 51.28      |
| II a                | 71 | 40           | 56.33      |
| II b                | 34 | 22           | 64.70      |
| III                 | 18 | 13           | 72.20      |
| IV                  | 03 | 03           | 100        |

**Discussion**

In this study, we evaluated the AChR antibody status in a large cohort of patients with myasthenia gravis. Studies on the AChR status in myasthenia gravis, using ELISA, are few. The present study thus becomes relevant, particularly in Indian context.

Compared to earlier studies on myasthenia gravis this study shows a significant male preponderance, with a male-female ratio of 1.5 : 1. This is in commensuration with an another study from India\cite{5} and a previous study from our institute.\cite{6} This perhaps reflects the larger number of men seeking medical consultation in India, as our hospital statistics also shows a M:F ratio of 3:2.

The sero prevalence of AchR antibody in different series was varied, being in the 67-93% range and these antibodies are virtually absent in normal controls or in patients with other neurological or immunological diseases.\cite{1,7} Jailkhani et al. used direct and indirect methods of ELISA and reported seropositivity in 90% of the patients of myasthenia gravis.\cite{3} The overall antibody positivity rate observed in the present study is 60%. Compared to other studies, the positivity rate is low and may reflect a rather low sensitivity of ELISA used in this study.

There was antibody positivity in 51.28% of the patients with ocular myasthenia. While these values are lower than patients with generalized MG, the difference was not statistically significant. Patients with ocular MG in general have lower AChR antibody levels ranging from 40-75%\cite{8,9}. They have the lowest mean antibody titer when measured against human limb muscle receptors, and in about 25% cases, the values are in the control range.\cite{9} However, it has been noted that their sera react well with ocular muscle receptors.\cite{7} This observation indicates that the antigenic differences between limb

| Parameter                           | Seropositive (n = 98) | Seronegative (n = 67) | P value |
|-------------------------------------|-----------------------|-----------------------|---------|
| Mean age at presentation (years)    | 37.8 ± 18.5           | 30.7 ± 18.5           | 0.01    |
| Age at onset (years)                | 35.2 ± 21.65          | 28.7 ± 19.27          | 0.05    |
| Gender ratio (M:F: 98:67)           | 64 : 34               | 34 : 33               | 0.06*   |
| Stage                               |                       |                       |         |
| Ocular V/s Others (39 :126)         | 20 :78                | 19 : 48               | 0.24*   |
| Mild V/s Severe (110 : 45)          | 60 : 38               | 50 : 17               | 0.07*   |
| Crisis at presentation (n = 20)     | 17                    | 3                     | 0.01    |
| Crisis at any time (n = 41)         | 30                    | 11                    | 0.05    |
| Thymic enlargement on chest CT**     | 41                    | 16                    | 0.21*   |
| Present (57): Absent (67)           |                       |                       |         |
| Remission (n = 28)                  | 16 : 82               | 12 : 55               | 0.79*   |
| Present (28): Absent (137)          |                       |                       |         |
| Deaths (n = 2)                      | 96 : 2                | 67 : 0                | 0.35*   |
| Present (2): Absent (163)           |                       |                       |         |

Mild = Stage I and IIA, *Not significant **Chest CT done in124, Severe = IIB, III, IV Others = IIA, IIB, III, IV
and ocular muscles may be responsible for the low positivity in ocular myasthenia. This also raises the possibility of the nature of the antibodies in ocular MG being different.

The role of thymus in the pathogenesis of myasthenia gravis is well-known. High antibody titers have been reported in patients with thymoma in MG.[1,7] In a previous study, it was noted that chest CT had a sensitivity of 73.1% and specificity of 75% in detecting thymic abnormalities.[10] In the present study, an abnormal thymus on CT did not predict the serological status. Approximately, 12-17% of patients with generalized MG lack demonstrable serum AChR antibodies, and they are referred to as the seronegative group.[11-14] Attempts have been made to characterize this subgroup. Soliven et al. reported that there was no difference in the age of onset, gender, duration of symptoms or frequency of crises between the seropositive and seronegative patients. [13] None of the patients in the seronegative group had thymic enlargement on CT, in contrast to seropositive group. But this difference was not statistically significant. Vincent et al. noted that seronegative patients tended to have shorter duration or symptoms restricted to ocular muscles.[11] Sanders et al. observed that seronegative patients were more likely to be males and have milder disease, ocular myasthenia and fewer thymomas.[14] Lindstrom et al. could not find any consistent similarity among seronegative patients. In the present study, it was noted that seropositive patients were older at presentation, had male preponderance and had more frequent occurrence of crises, both at presentation and at any time during the course of illness.

The newly discovered autoantibodies to muscle specific kinase (MuSK Antibodies) in the previously seronegative patients may help to understand the pathogenesis of seronegative patients. MuSK antibodies are reported to be present in two thirds of the AChR antibody negative patients.[13] In our series, the MuSK antibody status could not be assessed and so a comparison between the two groups could not be made.

In conclusion, this communication reports the result of AChR antibody assay in a large cohort of patients, using the direct and indirect ELISA technique. This brings about the usefulness of this simple diagnostic tool in the evaluation of patients with myasthenia. In addition, the characteristics of patients with seronegative myasthenia gravis have been described.

Acknowledgment

The authors wish to acknowledge the efforts of late Dr. Anisya Vasanth for initiating the study of AChR antibody assay at this center.

References

1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
2. Osseman KE, Genkis G. Studies in myasthenia gravis: Review of a 20 year experience in over 1200 patients. Mt Sinai J Med 1971;38:497-537.
3. Jalilkhani BL, Ashhana D, Jaffery NF, Kumar R, Ahuja GK. A simplified ELISA for anti-receptor antibodies in myasthenia gravis. J Immunol Met 1986;86:115-6.
4. Patil SA, Vasanth A, Christopher R, Sowbhagya P, Taly AB. Anti acetyl choline receptor antibodies in myasthenia gravis: NIMHANS experience. NIMHANS J 2000;18:33-7.
5. Kayal A, Chopra JS, Prabhakar S, Dhand UK, Singh H, Banerjee AK. Myasthenia Gravis, clinical profile and response to thymectomy. Neurol India 1985;33:265-71.
6. Ashraf VV, Taly AB, Vasanth A, Veerendrakumar M, Rao S. Myasthenia gravis: Clinical spectrum and long term follow up study. Ann Indian Acad Neurol 2005;8:7-13.
7. Vincent A, Newsom Davis J. Anti-acetylcholine receptor antibody. J Neurol Neurosurg Psychiatry 1980;43:590-600.
8. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis, Part 1 (Relation to clinical parameters in 250 patients). J Neurol Sci 1983:58:357-70.
9. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
10. Emani SR. Study of myasthenia gravis with special reference to thymectomy. Thesis submitted to National Institute of Mental Health and Neurosciences (Deemed University), Bangalore in part fulfillment for D.M.Degree in Neurology 2001.
11. Vincent A, Newsom Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-52.
12. Mossmann S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: A distinct disease entity. Lancet 1986;1:116-9.
13. Soliven BC, Lange DJ, Penn AS, Younger D, Jaretzki A 3rd, Lovelace RE, et al. Seronegative myasthenia gravis. Neurology 1988;38:514-7.
14. Sanders DB, Andrews Pi, Howard JF, Mossey JM. Seronegative myasthenia gravis. Neurology 1997;48:S40-5.
15. Hoch W, McConville J, Helms S, Newsom-Davis J, Helms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.